Trials
1 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.”In the company’s words, NCT06600412 on ClinicalTrials.gov
- Tested for
- Diabetic Kidney Disease
- Main trialPhase 2
- “The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease. The main questions it aims to answer are: 1. Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease? 2. Does R3R01 have an effect on kidney function and daily blood pressure? Researchers will compare the results…”In the company’s words, NCT06600412 on ClinicalTrials.gov
Other drugs for Diabetic Kidney Disease
- WAL0921Walden Biosciences · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- ALN-ANG3Regeneron · Phase 2
- EvinacumabRegeneron · Phase 2
- AtrasentanNovartis · Phase 2
Coming up1
- 1 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Apr 2027 | The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. | |
| Phase 2Completed | 21 May 2025 | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026